Rapsyn congenital myasthenic syndrome worsened by fluoxetine.
Muscle Nerve
; 55(1): 131-135, 2017 01.
Article
em En
| MEDLINE
| ID: mdl-27397848
ABSTRACT
INTRODUCTION:
Fluoxetine is a selective serotonin reuptake inhibitor and long-lived open channel blocker of the acetylcholine receptor, often used in the treatment of slow-channel congenital myasthenic syndromes (CMS).METHODS:
We report a 42-year-old woman who had a history of episodic limb weakness that worsened after initiation of fluoxetine for treatment of depression. Genetic testing for CMS revealed a homozygous pathogenic mutation in the rapsyn (RAPSN) gene (p.Asn88Lys). Electrodiagnostic testing was performed before and 1 month after discontinuation of fluoxetine.RESULTS:
The 2 Hz repetitive nerve stimulation of the fibular and spinal accessory nerves showed a baseline decrement of 36% and 14%, respectively. One month after discontinuing fluoxetine, the spinal accessory nerve decrement was no longer present, and the decrement in the fibular nerve was improved at 17%.CONCLUSIONS:
This case demonstrates worsening of both clinical and electrophysiologic findings in a patient with CMS secondary to a RAPSN mutation treated with fluoxetine. Muscle Nerve 55 131-135, 2017.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Fluoxetina
/
Antidepressivos de Segunda Geração
/
Síndromes Miastênicas Congênitas
/
Proteínas Musculares
/
Mutação
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Muscle Nerve
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Estados Unidos